Compare Amphastar Pharmaceuticals Inc (AMPH) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Quantumscape Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.91 (market cap $868.62M), while Quantumscape Corp trades at $6.34 (market cap $3.90B). The key difference: Quantumscape Corp is far larger — about 4.5× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| AMPH | QS | |
|---|---|---|
Market Cap | $868.62M | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $18.44 |
52-Week Low | $16.87 | $4.89 |
Enterprise Value | $1.27B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
QuantumScape (QS) trades at $6.19, up 1.89% today, with a mixed technical outlook showing bullish oscillators but bearish moving averages. The company remains pre-revenue with significant losses, reporting a net income of -$435.05M in 2025 (company filing, 2025). Recent Q2 2026 earnings beat expectations but highlighted ongoing commercialization delays, with solid-state battery targets pushed to 2029 (The Motley Fool, 2026-08-11).
The stock presents high-risk speculation due to zero revenue and persistent cash burn, offset by potential long-term disruption in battery technology. Analyst sentiment is cautious with 73% hold ratings, reflecting skepticism on near-term execution. Key risks include timeline slippage, funding needs, and competitive pressure in the EV supply chain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
